Option Care Health (NASDAQ:OPCH – Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided EPS guidance of 1.590-1.690 for the period, compared to the consensus EPS estimate of 1.240. The company issued revenue guidance of $5.2 billion-$5.4 billion, compared to the consensus revenue estimate of $5.2 billion. Option Care Health also updated its FY 2024 guidance to 1.550-1.590 EPS.
Wall Street Analyst Weigh In
Several brokerages have weighed in on OPCH. Truist Financial lowered their price target on shares of Option Care Health from $41.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Bank of America upgraded shares of Option Care Health from a “neutral” rating to a “buy” rating and lifted their target price for the company from $26.00 to $33.00 in a research note on Monday. The Goldman Sachs Group lowered Option Care Health from a “buy” rating to a “neutral” rating and cut their price target for the stock from $38.00 to $27.00 in a research note on Monday, November 4th. Jefferies Financial Group downgraded Option Care Health from a “buy” rating to a “hold” rating and lowered their price objective for the company from $38.00 to $26.00 in a research report on Thursday, October 31st. Finally, Barrington Research cut their target price on Option Care Health from $40.00 to $32.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Option Care Health presently has an average rating of “Moderate Buy” and an average price target of $29.71.
Get Our Latest Research Report on OPCH
Option Care Health Stock Up 15.5 %
Insider Activity at Option Care Health
In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. bought 43,000 shares of Option Care Health stock in a transaction dated Friday, November 8th. The shares were purchased at an average cost of $22.54 per share, for a total transaction of $969,220.00. Following the acquisition, the director now directly owns 326,334 shares in the company, valued at approximately $7,355,568.36. This represents a 15.18 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.64% of the stock is owned by corporate insiders.
About Option Care Health
Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
Featured Stories
- Five stocks we like better than Option Care Health
- Consumer Staples Stocks, Explained
- 3 Stocks to Benefit From China’s Rare Earth Export Ban on U.S.
- What Are Treasury Bonds?
- Why Goldman Sachs Just Upgraded These 3 Stocks and What It Means
- Bank Stocks – Best Bank Stocks to Invest In
- Analyst Upgrade Shows Over Double Bagger Potential for BigBear.ai
Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.